Foresee Pharmaceuticals Gains Chinese Approval for CAMCEVI 42 mg

The regulatory clearance marks a milestone for the drug’s global expansion. CAMCEVI 42 mg, a ready-to-use formulation of leuprolide mesylate, provides an alternative to existing therapies by reducing the frequency of dosing required for patients. Dr. Ben Chien, Chairman and CEO of Foresee Pharmaceuticals, noted that the launch through their partner, GenSci, serves as a vital step in scaling the company’s international franchise.

Beyond prostate cancer, the partnership between the two companies encompasses a broader clinical pipeline. GenSci holds exclusive rights to commercialize the drug in China for indications including central precocious puberty and premenopausal breast cancer. In May 2026, the partner submitted a supplemental New Drug Application for the treatment of premenopausal breast cancer, which currently remains under substantive review by Chinese regulators. Foresee continues to leverage its Stabilized Injectable Formulation technology, with plans to extend its application into the central nervous system field by 2027.